

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT UPDATE ON AN INVESTIGATIONAL ONCOLOGY DRUG PRODUCT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**” or “**Lee’s Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that, on 29 July 2025, Socazolimab, an oncology drug product of China Oncology Focus Limited (“**COF**”), a subsidiary of the Company, has been approved for marketing in combination with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (“**ES-SCLC**”) in Mainland China by National Medical Products Administration (“**NMPA**”).

The approval is based on a Phase III, multicenter, randomised, double blinded, placebo control clinical trial of Socazolimab combined with chemotherapy. The trial involved 54 centers and was led by Prof. Shun Lu (陸舜) from Shanghai Chest Hospital (上海市胸科醫院). The results indicated that patients treated with Socazolimab presented significant overall survival benefit (13.90 months) compared with the placebo group (11.58 months) and the drug did not increase the safety risk of the treatment.

Socazolimab is a fully human anti-PD-L1 monoclonal antibody developed to treat cancer. To date, the drug has been approved in recurrent or metastatic cervical cancer and first-line treatment of extensive-stage small-cell lung cancer. Another phase III clinical trial is on-going in the first-line treatment in persistent, recurrent, or metastatic cervical cancer.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 30 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 20 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. More information available at www.leespharm.com.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 31 July 2025

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors; Dr. Li Xiaoyi, Mr. James Charles Gale and Mr. Huang Zuie-Chin are non-executive Directors; and Dr. Chan Yau Ching, Bob, Ms. Cheang Yee Wah, Eva and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.

* *For identification purpose only*